Treatment of HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis: Toward Rational Targeted Therapy

Neurologic Clinics

Volumn 26, Issue 3, 2008, Pages 781-797

  Oh, Unsong ^a   Jacobson, Steven ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; BETA1A INTERFERON; CORTICOSTEROID DERIVATIVE; DACLIZUMAB; DANAZOL; HLA A ANTIGEN; HLA DR ANTIGEN; HU MIK BETA1; IMMUNOGLOBULIN; INTERFERON; INTERLEUKIN 15; INTERLEUKIN 15 RECEPTOR ALPHA; INTERLEUKIN 2; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; VALPROIC ACID; ZIDOVUDINE;

ALLELE; CEREBROSPINAL FLUID; CLINICAL FEATURE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; HEREDITARY MOTOR SENSORY NEUROPATHY; HISTOPATHOLOGY; HUMAN; HUMAN T CELL LEUKEMIA VIRUS 1; LYME DISEASE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PLASMAPHERESIS; PRIMARY LATERAL SCLEROSIS; PRIORITY JOURNAL; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RISK FACTOR; SPASTIC PARAPLEGIA; SPINAL CORD DISEASE; SUBACUTE COMBINED DEGENERATION; UPREGULATION; VIRUS LOAD; WORLD HEALTH ORGANIZATION;

ASTROCYTES; BRAIN; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; DRUG THERAPY; HUMANS; NERVE DEGENERATION; PARAPARESIS, TROPICAL SPASTIC; POLYMERASE CHAIN REACTION; RISK FACTORS; SPINAL CORD;

EID: 47649123935     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2008.03.008     Document Type: Review

References (95)

1. Gessain A., Barin F., Vernant J.C., et al. Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis. Lancet 2 8452 (1985) 407-410
2. Osame M., Usuku K., Izumo S., et al. HTLV-I associated myelopathy, a new clinical entity. Lancet 1 8488 (1986) 1031-1032
3. Poiesz B.J., Ruscetti F.W., Reitz M.S., et al. Isolation of a new type C retrovirus (HTLV) in primary uncultured cells of a patient with Sezary T-cell leukaemia. Nature 294 5838 (1981) 268-271
4. Poiesz B.J., Ruscetti F.W., Gazdar A.F., et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma. Proc Natl Acad Sci U S A 77 12 (1980) 7415-7419
5. Richardson J.H., Edwards A.J., Cruickshank J.K., et al. In vivo cellular tropism of human T-cell leukemia virus type 1. J Virol 64 11 (1990) 5682-5687
6. Nagai M., Brennan M.B., Sakai J.A., et al. CD8(+) T cells are an in vivo reservoir for human T-cell lymphotropic virus type I. Blood 98 6 (2001) 1858-1861
7. Trejo S.R., and Ratner L. The HTLV receptor is a widely expressed protein. Virology 268 1 (2000) 41-48
8. Lehky T.J., Fox C.H., Koenig S., et al. Detection of human T-lymphotropic virus type I (HTLV-I) tax RNA in the central nervous system of HTLV-I-associated myelopathy/tropical spastic paraparesis patients by in situ hybridization. Ann Neurol 37 2 (1995) 167-175
9. Blattner W.A., and Gallo R.C. Epidemiology of human retroviruses. Leuk Res 9 6 (1985) 697-698
10. Gessain A. Epidemiology of HTLV-I and associated diseases. In: Hollsberg P., and Hafler D. (Eds). Human T-cell lymphotropic virus type I (1996), John Wiley and Sons, Chichester (UK) 33-64
11. Kaplan J.E., Osame M., Kubota H., et al. The risk of development of HTLV-I-associated myelopathy/tropical spastic paraparesis among persons infected with HTLV-I. J Acquir Immune Defic Syndr 3 11 (1990) 1096-1101
12. Tosswill J.H., Taylor G.P., Tedder R.S., et al. HTLV-I/II associated disease in England and Wales, 1993-7: retrospective review of serology requests. BMJ 320 7235 (2000) 611-612
13. Orland J.R., Engstrom J., Fridey J., et al. Prevalence and clinical features of HTLV neurologic disease in the HTLV Outcomes Study. Neurology 61 11 (2003) 1588-1594
14. Morgan O.S., Rodgers-Johnson P., Mora C., et al. HTLV-1 and polymyositis in Jamaica. Lancet 2 8673 (1989) 1184-1187
15. Higuchi I., Hashimoto K., Kashio N., et al. Detection of HTLV-I provirus by in situ polymerase chain reaction in mononuclear inflammatory cells in skeletal muscle of viral carriers with polymyositis. Muscle Nerve 18 8 (1995) 854-858
16. Leite A.C., Silva M.T., Alamy A.H., et al. Peripheral neuropathy in HTLV-I infected individuals without tropical spastic paraparesis/HTLV-I-associated myelopathy. J Neurol 251 7 (2004) 877-881
17. Kiwaki T., Umehara F., Arimura Y., et al. The clinical and pathological features of peripheral neuropathy accompanied with HTLV-I associated myelopathy. J Neurol Sci 206 1 (2003) 17-21
18. Mochizuki M., Watanabe T., Yamaguchi K., et al. HTLV-I uveitis: a distinct clinical entity caused by HTLV-I. Jpn J Cancer Res 83 3 (1992) 236-239
19. Buggage R.R. Ocular manifestations of human T-cell lymphotropic virus type 1 infection. Curr Opin Ophthalmol 14 6 (2003) 420-425
20. Nishioka K., Maruyama I., Sato K., et al. Chronic inflammatory arthropathy associated with HTLV-I. Lancet 1 8635 (1989) 441
21. Zucker-Franklin D. Non-HIV retroviral associations with rheumatic disease. Curr Rheumatol Rep 2 2 (2000) 156-162
22. Sugimoto M., Nakashima H., Watanabe S., et al. T-lymphocyte alveolitis in HTLV-I-associated myelopathy. Lancet 2 8569 (1987) 1220
23. Igakura T., Stinchcombe J.C., Goon P.K., et al. Spread of HTLV-I between lymphocytes by virus-induced polarization of the cytoskeleton. Science 299 5613 (2003) 1713-1716
24. Taylor G.P., Goon P., Furukawa Y., et al. Zidovudine plus lamivudine in Human T-Lymphotropic Virus type-I-associated myelopathy: a randomised trial. Retrovirology 3 (2006) 63-71
25. Taylor G.P., Hall S.E., Navarrete S., et al. Effect of lamivudine on human T-cell leukemia virus type 1 (HTLV-1) DNA copy number, T-cell phenotype, and anti-tax cytotoxic T-cell frequency in patients with HTLV-1-associated myelopathy. J Virol 73 12 (1999) 10289-10295
26. Grant C., Barmak K., Alefantis T., et al. Human T cell leukemia virus type I and neurologic disease: events in bone marrow, peripheral blood, and central nervous system during normal immune surveillance and neuroinflammation. J Cell Physiol 190 2 (2002) 133-159
27. Jacobson S., Shida H., McFarlin D.E., et al. Circulating CD8+ cytotoxic T lymphocytes specific for HTLV-I pX in patients with HTLV-I associated neurological disease. Nature 348 6298 (1990) 245-248
28. Nagai M., and Jacobson S. Immunopathogenesis of human T cell lymphotropic virus type I-associated myelopathy. Curr Opin Neurol 14 3 (2001) 381-386
29. Nagai M., Usuku K., Matsumoto W., et al. Analysis of HTLV-I proviral load in 202 HAM/TSP patients and 243 asymptomatic HTLV-I carriers: high proviral load strongly predisposes to HAM/TSP. J Neurovirol 4 6 (1998) 586-593
30. Manns A., Miley W.J., Wilks R.J., et al. Quantitative proviral DNA and antibody levels in the natural history of HTLV-I infection. J Infect Dis 180 5 (1999) 1487-1493
31. Jeffery K.J., Usuku K., Hall S.E., et al. HLA alleles determine human T-lymphotropic virus-I (HTLV-I) proviral load and the risk of HTLV-I-associated myelopathy. Proc Natl Acad Sci U S A 96 7 (1999) 3848-3853
32. Vine A.M., Witkover A.D., Lloyd A.L., et al. Polygenic control of human T lymphotropic virus type I (HTLV-I) provirus load and the risk of HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 186 7 (2002) 932-939
33. Olindo S., Cabre P., Lezin A., et al. Natural history of human T-lymphotropic virus 1-associated myelopathy: a 14-year follow-up study. Arch Neurol 63 11 (2006) 1560-1566
34. Report of the Scientific Group on HTLV-I Infections and Associated Diseases. World Health Organization Report (WP) CDS (S) / ICP / PHC / 014. 1988.
35. De Castro-Costa C.M., Araujo A.Q., Barreto M.M., et al. Proposal for diagnostic criteria of tropical spastic paraparesis/HTLV-I-associated myelopathy (TSP/HAM). AIDS Res Hum Retroviruses 22 10 (2006) 931-935
36. Alcindor F., Valderrama R., Canavaggio M., et al. Imaging of human T-lymphotropic virus type I-associated chronic progressive myeloneuropathies. Neuroradiology 35 1 (1992) 69-74
37. Kira J., Fujihara K., Itoyama Y., et al. Leukoencephalopathy in HTLV-I-associated myelopathy/tropical spastic paraparesis: MRI analysis and a two year follow-up study after corticosteroid therapy. J Neurol Sci 106 1 (1991) 41-49
38. Kuroda Y., Matsui M., Yukitake M., et al. Assessment of MRI criteria for MS in Japanese MS and HAM/TSP. Neurology 45 1 (1995) 30-33
39. Puccioni-Sohler M., Yamano Y., Rios M., et al. Differentiation of HAM/TSP from patients with multiple sclerosis infected with HTLV-I. Neurology 68 3 (2007) 206-213
40. Takenouchi N., Yamano Y., Usuku K., et al. Usefulness of proviral load measurement for monitoring of disease activity in individual patients with human T-lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis. J Neurovirol 9 1 (2003) 29-35
41. Lezin A., Olindo S., Oliere S., et al. Human T lymphotropic virus type I (HTLV-I) proviral load in cerebrospinal fluid: a new criterion for the diagnosis of HTLV-I-associated myelopathy/tropical spastic paraparesis?. J Infect Dis 191 11 (2005) 1830-1834
42. Levin M.C., and Jacobson S. HTLV-I associated myelopathy/tropical spastic paraparesis (HAM/TSP): a chronic progressive neurologic disease associated with immunologically mediated damage to the central nervous system. J Neurovirol 3 2 (1997) 126-140
43. Izumo S., Ijichi T., Higuchi I., et al. Neuropathology of HTLV-I-associated myelopathy-a report of two autopsy cases. Acta Paediatr Jpn 34 3 (1992) 358-364
44. Iwasaki Y. Pathology of chronic myelopathy associated with HTLV-I infection (HAM/TSP). J Neurol Sci 96 1 (1990) 103-123
45. Cartier L.M., Cea J.G., Vergara C., et al. Clinical and neuropathological study of six patients with spastic paraparesis associated with HTLV-I: an axomyelinic degeneration of the central nervous system. J Neuropathol Exp Neurol 56 4 (1997) 403-413
46. Iwasaki Y., Ohara Y., Kobayashi I., et al. Infiltration of helper/inducer T lymphocytes heralds central nervous system damage in human T-cell leukemia virus infection. Am J Pathol 140 5 (1992) 1003-1008
47. Aye M.M., Matsuoka E., Moritoyo T., et al. Histopathological analysis of four autopsy cases of HTLV-I-associated myelopathy/tropical spastic paraparesis: inflammatory changes occur simultaneously in the entire central nervous system. Acta Neuropathol (Berl) 100 3 (2000) 245-252
48. Nagai M., Yamano Y., Brennan M.B., et al. Increased HTLV-I proviral load and preferential expansion of HTLV-I Tax-specific CD8+ T cells in cerebrospinal fluid from patients with HAM/TSP. Ann Neurol 50 6 (2001) 807-812
49. Umehara F., Izumo S., Nakagawa M., et al. Immunocytochemical analysis of the cellular infiltrate in the spinal cord lesions in HTLV-I-associated myelopathy. J Neuropathol Exp Neurol 52 4 (1993) 424-430
50. Umehara F., Izumo S., Ronquillo A.T., et al. Cytokine expression in the spinal cord lesions in HTLV-I-associated myelopathy. J Neuropathol Exp Neurol 53 1 (1994) 72-77
51. Umehara F., Okada Y., Fujimoto N., et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in HTLV-I-associated myelopathy. J Neuropathol Exp Neurol 57 9 (1998) 839-849
52. Osame M. Pathological mechanisms of human T-cell lymphotropic virus type I-associated myelopathy (HAM/TSP). J Neurovirol 8 5 (2002) 359-364
53. Fujinami R.S., and Oldstone M.B. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 230 4729 (1985) 1043-1045
54. Levin M.C., Lee S.M., Kalume F., et al. Autoimmunity due to molecular mimicry as a cause of neurological disease. Nat Med 8 5 (2002) 509-513
55. Harrington Jr. W.J., Sheremata W.A., Snodgrass S.R., et al. Tropical spastic paraparesis/HTLV-1-associated myelopathy (TSP/HAM): treatment with an anabolic steroid danazol. AIDS Res Hum Retroviruses 7 12 (1991) 1031-1034
56. Shirabe S., Nakamura T., Tsujino A., et al. Successful application of pentoxifylline in the treatment of HTLV-I associated myelopathy. J Neurol Sci 151 1 (1997) 97-101
57. Wodarz D., Nowak M.A., and Bangham C.R. The dynamics of HTLV-I and the CTL response. Immunol Today 20 5 (1999) 220-227
58. Matsuzaki T., Nakagawa M., Nagai M., et al. HTLV-I proviral load correlates with progression of motor disability in HAM/TSP: analysis of 239 HAM/TSP patients including 64 patients followed up for 10 years. J Neurovirol 7 3 (2001) 228-234
59. Olindo S., Lezin A., Cabre P., et al. HTLV-1 proviral load in peripheral blood mononuclear cells quantified in 100 HAM/TSP patients: a marker of disease progression. J Neurol Sci 237 1-2 (2005) 53-59
60. Saito M., Nakagawa M., Kaseda S., et al. Decreased human T lymphotropic virus type I (HTLV-I) provirus load and alteration in T cell phenotype after interferon-alpha therapy for HTLV-I-associated myelopathy/tropical spastic paraparesis. J Infect Dis 189 1 (2004) 29-40
61. Yamano Y., Nagai M., Brennan M., et al. Correlation of human T-cell lymphotropic virus type 1 (HTLV-1) mRNA with proviral DNA load, virus-specific CD8(+) T cells, and disease severity in HTLV-1-associated myelopathy (HAM/TSP). Blood 99 1 (2002) 88-94
62. Oh U., Yamano Y., Mora C.A., et al. Interferon-beta1a therapy in human T-lymphotropic virus type I-associated neurologic disease. Ann Neurol 57 4 (2005) 526-534
63. Kubota R., Nagai M., Kawanishi T., et al. Increased HTLV type 1 tax specific CD8+ cells in HTLV type 1-asociated myelopathy/tropical spastic paraparesis: correlation with HTLV type 1 proviral load. AIDS Res Hum Retroviruses 16 16 (2000) 1705-1709
64. Nagai M., Kubota R., Greten T.F., et al. Increased activated human T cell lymphotropic virus type I (HTLV-I) Tax11-19-specific memory and effector CD8+ cells in patients with HTLV-I-associated myelopathy/tropical spastic paraparesis: correlation with HTLV-I provirus load. J Infect Dis 183 2 (2001) 197-205
65. Parker C.E., Daenke S., Nightingale S., et al. HTLV-1-specific cytotoxic T-lymphocytes are found in healthy seropositives as well as in patients with tropical spastic paraparesis. Virology 188 2 (1992) 628-636
66. Asquith B., Mosley A.J., Barfield A., et al. A functional CD8+ cell assay reveals individual variation in CD8+ cell antiviral efficacy and explains differences in human T-lymphotropic virus type 1 proviral load. J Gen Virol 86 Pt 5 (2005) 1515-1523
67. Azimi N., Brown K., Bamford R.N., et al. Human T cell lymphotropic virus type I Tax protein trans-activates interleukin 15 gene transcription through an NF-kappaB site. Proc Natl Acad Sci U S A 95 5 (1998) 2452-2457
68. Tendler C.L., Greenberg S.J., Blattner W.A., et al. Transactivation of interleukin 2 and its receptor induces immune activation in human T-cell lymphotropic virus type I-associated myelopathy: pathogenic implications and a rationale for immunotherapy. Proc Natl Acad Sci U S A 87 13 (1990) 5218-5222
69. Azimi N., Jacobson S., Leist T., et al. Involvement of IL-15 in the pathogenesis of human T lymphotropic virus type I-associated myelopathy/tropical spastic paraparesis: implications for therapy with a monoclonal antibody directed to the IL-2/15R beta receptor. J Immunol 163 7 (1999) 4064-4072
70. Waldmann T.A., Dubois S., and Tagaya Y. Contrasting roles of IL-2 and IL-15 in the life and death of lymphocytes: implications for immunotherapy. Immunity 14 2 (2001) 105-110
71. Yamano Y., Takenouchi N., Li H.C., et al. Virus-induced dysfunction of CD4(+)CD25(+) T cells in patients with HTLV-I-associated neuroimmunological disease. J Clin Invest 115 5 (2005) 1361-1368
72. Oh U., Grant C., Griffith C., et al. Reduced Foxp3 protein expression is associated with inflammatory disease during human t lymphotropic virus type 1 Infection. J Infect Dis 193 11 (2006) 1557-1566
73. Grant C, Oh U, Yao K, et al. Dysregulation of TGF-β signaling and regulatory and effector T cell function in virus-induced neuroinflammatory disease. Manuscript accepted for publication.
74. Yoshimi Akahta, et al. submitted for publication.
75. Osame M., Matsumoto M., Usuku K., et al. Chronic progressive myelopathy associated with elevated antibodies to human T-lymphotropic virus type I and adult T-cell leukemialike cells. Ann Neurol 21 2 (1987) 117-122
76. Cupps T.R., and Fauci A.S. Corticosteroid-mediated immunoregulation in man. Immunol Rev 65 (1982) 133-155
77. Gessain A., and Gout O. Chronic myelopathy associated with human T-lymphotropic virus type I (HTLV-I). Ann Intern Med 117 11 (1992) 933-946
78. Matsuo H., Nakamura T., Tsujihata M., et al. Plasmapheresis in treatment of human T-lymphotropic virus type-I associated myelopathy. Lancet 2 8620 (1988) 1109-1113
79. Kuroda Y., Takashima H., Ikeda A., et al. Treatment of HTLV-I-associated myelopathy with high-dose intravenous gammaglobulin. J Neurol 238 6 (1991) 309-314
80. Gold R., Stangel M., and Dalakas M.C. Drug Insight: the use of intravenous immunoglobulin in neurology-therapeutic considerations and practical issues. Nat Clin Pract Neurol 3 1 (2007) 36-44
81. Yamano Y., Cohen C.J., Takenouchi N., et al. Increased expression of human T lymphocyte virus type I (HTLV-I) Tax11-19 peptide-human histocompatibility leukocyte antigen A*201 complexes on CD4+ CD25+ T cells detected by peptide-specific, major histocompatibility complex-restricted antibodies in patients with HTLV-I-associated neurologic disease. J Exp Med 199 10 (2004) 1367-1377
82. Waldmann T.A., White J.D., Goldman C.K., et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood 82 6 (1993) 1701-1712
83. Junghans R.P., Waldmann T.A., Landolfi N.F., et al. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor with new features for immunotherapy in malignant and immune disorders. Cancer Res 50 5 (1990) 1495-1502
84. Lehky T.J., Levin M.C., Kubota R., et al. Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac. Ann Neurol 44 6 (1998) 942-947
85. Izumo S., Goto I., Itoyama Y., et al. Interferon-alpha is effective in HTLV-I-associated myelopathy: a multicenter, randomized, double-blind, controlled trial. Neurology 46 4 (1996) 1016-1021
86. Yamasaki K., Kira J., Koyanagi Y., et al. Long-term, high dose interferon-alpha treatment in HTLV-I-associated myelopathy/tropical spastic paraparesis: a combined clinical, virological and immunological study. J Neurol Sci 147 2 (1997) 135-144
87. Gout O., Gessain A., Iba-Zizen M., et al. The effect of zidovudine on chronic myelopathy associated with HTLV-1. J Neurol 238 2 (1991) 108-109
88. Sheremata W.A., Benedict D., Squilacote D.C., et al. High-dose zidovudine induction in HTLV-I-associated myelopathy: safety and possible efficacy. Neurology 43 10 (1993) 2125-2129
89. Derse D., Hill S.A., Lloyd P.A., et al. Examining human T-lymphotropic virus type 1 infection and replication by cell-free infection with recombinant virus vectors. J Virol 75 18 (2001) 8461-8468
90. Balestrieri E., Forte G., Matteucci C., et al. Effect of lamivudine on transmission of human T-cell lymphotropic virus type 1 to adult peripheral blood mononuclear cells in vitro. Antimicrobial Agents Chemother 46 9 (2002) 3080-3083
91. McInnes I.B., and Gracie J.A. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 4 4 (2004) 392-397
92. Azimi N., Nagai M., Jacobson S., et al. IL-15 plays a major role in the persistence of Tax-specific CD8 cells in HAM/TSP patients. Proc Natl Acad Sci U S A 98 25 (2001) 14559-14564
93. Ylisastigui L., Archin N.M., Lehrman G., et al. Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression. AIDS 18 8 (2004) 1101-1108
94. Lehrman G., Hogue I.B., Palmer S., et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 366 9485 (2005) 549-555
95. Lezin A., Gillet N., Olindo S., et al. Histone deacetylase mediated transcriptional activation reduces proviral loads in HTLV-1 associated myelopathy/tropical spastic paraparesis patients. Blood 110 (2007) 3722-3728